ESCRS 2023: Presbyopia treatment with microporation therapeutic technology by Ace Vision Group
AnnMarie Hipsley, DPT, PhD, Founder and CEO of Ace Vision Group, met with Ophthalmology Times Europe at the 2023 European Society of Cataract and Refractive Surgeons to discuss Ace Vision Group’s microporation therapeutic technology, used to treat presbyopia.
Explore More Articles
Ace Vision Group Announces Initial Close of $29.4 Million Series B Financing Round
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) — Ace Vision Group, Inc, (“AVG” or “the Company”) an emerging medical device company pioneering Laser Scleral Microporation (LSM) therapy for age-related vision loss, today announced the successful close of a $29.4 million Series B financing round.
read moreIN-OFFICE SURGICAL PROCEDURES FOR PRESBYOPIA
In-office procedures offer ophthalmic surgeons and patients the greatest flexibility and efficiency of scheduling. Procedures such as YAG capsulotomy, select laser trabeculoplasty, laser pupil iridoplasty, LASIK/PRK/SMILE and minor lid procedures are routinely done within the in-office surgery suite. A large 2016 study demonstrated the safety and outcomes of cataract procedures performed within the surgeon’s office, …
read moreLaser scleral microporation treatment may be ‘game changer’ for presbyopia
CARLSBAD, Calif. — In this Healio Video Perspective from the Women in Ophthalmology Summer Symposium, Dagny Zhu, MD, and AnnMarie Hipsley, DPT, PhD, discuss laser scleral microporation for presbyopia. Hipsley said it is important to understand that presbyopia is an aging disease rather than a refractive disorder. Catching it early and treating it can be beneficial for patients. Zhu said laser …
read more